RxDoctor Payments Data

Ali Hamzei, MD

Clinical Cardiac Electrophysiology · Encinitas, CANPI 1376511188

Payments from drug & device makers

$43,471in general payments, 2019–2025

Across 550 payments — averaging $79.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$18K
  • Boston Scientific$8K
  • Biotronik Inc.$4K
  • Abbott$3K
  • Pfizer$977
  • Sanofi-aventis U.S. LLC$834
  • plus $8K from 42 others

What the payments were for

  • Consulting fees$14,28833%
  • Travel & lodging$11,67227%
  • Food & beverage$17,49440%
  • Education$180%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$43,471 in reported general payments places this provider in the 50th percentile of 290 clinical cardiac electrophysiology providers in California.

See all clinical cardiac electrophysiology providers in California

Medicare billing

Part B allowed, 2024
$887,113
Medicare patients
1,782
Services billed
10,147

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban179$249,623
XareltoRivaroxaban38$59,178
EntrestoSacubitril/Valsartan14$23,741
FarxigaDapagliflozin Propanediol11$9,343
Dofetilide16$6,708
Propafenone Hcl69$2,904
Metoprolol Succinate145$2,524
SotalolSotalol Hcl115$2,190
Flecainide Acetate61$1,608
Diltiazem 24hr Er (Cd)Diltiazem Hcl52$1,584
Losartan Potassium81$1,579
Amiodarone Hcl15$1,393
Digoxin27$739
Rosuvastatin Calcium28$620
Amlodipine Besylate30$487

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$977$249,623179 claims
Johnson & JohnsonXarelto$224$59,17838 claims
NovartisEntresto$674$23,74114 claims
AstraZenecaFarxiga$296$9,34311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 290 clinical cardiac electrophysiology providers in California.

Other clinical cardiac electrophysiology in Encinitas

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →